Sylvester Comprehensive Cancer Center

  • 20200609 - Beitinjaneh Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:
    RCemailImg Robby Friedman
    RCphone +1 (561) 7060311

    IRB: 20200609

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other

    Sponsor: AUTOLUS

    Enrolling Sites:

    Sylvester

    Title:

    An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating The Safety And Efficacy Of AUTO1, A CAR T Cell Treatment Targeting CD19, In Adult Patients With Relapsed Or Refractory B Cell Acute Lymphoblastic Leukaemia

    Eligibility Criteria - NCT04404660 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190932 - Bradley Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:

    IRB: 20190932

    SDG: Leukemia/heme
    Disease Site(s):

    Other Hematopoietic

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester

    Title:

    Investigator Initiated Trial of the LSD1 Inhibitor IMG-7289 for the Treatment of Patients with Essential Thrombocythemia (ET) or Polycythemia Vera (PV) That Have Failed at Least One Standard Therapy

    Eligibility Criteria - NCT04262141 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190961 - Bradley Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:

    IRB: 20190961

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other,Leukemia, not otherwise specified,Myeloid and Monocytic Leukemia,Other Hematopoietic

    Sponsor: FORTY SEVEN, INC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination with Azacitidine in Patients with Hematological Malignancies

    Eligibility Criteria - NCT03248479 *This information has been extracted from " www.clinicaltrials.gov"

  • SEL 120 - Bradley, Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20191267

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other,Myeloid and Monocytic Leukemia,Other Hematopoietic

    Sponsor: SELVITA

    Enrolling Sites:

    Sylvester

    Title:

    A Phase Ib Study of SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

    Eligibility Criteria - NCT04021368 *This information has been extracted from " www.clinicaltrials.gov"

  • 5F9009 - Bradley, Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:

    IRB: 20200862

    SDG: Leukemia/heme
    Disease Site(s):

    Multiple

    Sponsor: FORTY SEVEN, INC

    Enrolling Sites:

    Deerfield
    Plantation
    Sylvester

    Title:

    A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination With Azacitidine Versus Azacitidine Plus Placebo in Treatment-na´ve Patients With Higher Risk Myelodysplastic Syndrome

    Eligibility Criteria - NCT04313881 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210379 - Bradley Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:

    IRB: 20210379

    SDG: Leukemia/heme
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Gilead Sciences, Inc.

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies

    Eligibility Criteria - NCT04778410 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210527 - Bradley Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:

    IRB: 20210527

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, not otherwise specified,Myeloid and Monocytic Leukemia

    Sponsor: Constellation Pharmaceuticals

    Enrolling Sites:

    Deerfield
    Plantation
    Sylvester

    Title:

    A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

    Eligibility Criteria - NCT04603495 *This information has been extracted from " www.clinicaltrials.gov"

  • SPN-00900 - Bradley, Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:

    IRB: 20211051

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other,Leukemia, not otherwise specified

    Sponsor: Geron

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat and in Combination with Ruxolitinib in Patients with Myelofibrosis.

  • ATRC-101-A01 - Chandhok, Namrata

  • Investigator:
    Namrata Chandhok
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20200937

    SDG: Leukemia/heme
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: Aptose Biosciences

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1a/b Trial of CG-806 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes

    Eligibility Criteria - NCT03893682 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201405 - Chandhok Namrata

  • Investigator:
    Namrata Chandhok
    RCname Email

    Coordinator:

    IRB: 20201405

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other

    Sponsor: ETCTN

    Enrolling Sites:

    Sylvester

    Title:

    The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

    Eligibility Criteria - NCT03953898 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201430 - Chandhok Namrata

  • Investigator:
    Namrata Chandhok
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20201430

    SDG: Leukemia/heme
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: Incyte Corporation

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma

    Eligibility Criteria - NCT04582539 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200492 - Jimenez Antonio

  • Investigator:
    Antonio Jimenez
    RCname Email

    Coordinator:

    IRB: 20200492

    SDG: Leukemia/heme
    Disease Site(s):

    Multiple

    Sponsor: BMT CTN

    Enrolling Sites:

    Plantation
    Sylvester

    Title:

    Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D)

    Eligibility Criteria - NCT03904134 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201214 - Jimenez Antonio

  • Investigator:
    Antonio Jimenez
    RCname Email

    Coordinator:

    IRB: 20201214

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other,Lymphoid Leukemia,Myeloid and Monocytic Leukemia

    Sponsor: Orca Biosystems

    Enrolling Sites:

    Sylvester

    Title:

    A Phase Ib/Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation with Either Ocra-T, T-cell-Depleted Graft with Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft

    Eligibility Criteria - NCT04013685 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201503 - Sekeres Mikkael

  • Investigator:
    Mikkael Sekeres
    RCname Email

    Coordinator:

    IRB: 20201503

    SDG: Leukemia/heme
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: SCCC

    Enrolling Sites:

    Cleveland Clinic Ohio
    Sylvester

    Title:

    A multicenter, Phase Ib/II study that combines Luspatercept and Lenalidomide (L2) in lower-risk, non-del(5q) MDS Patients

    Eligibility Criteria - NCT04539236 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210499 - Sekeres Mikkael

  • Investigator:
    Mikkael Sekeres
    RCname Email

    Coordinator:

    IRB: 20210499

    SDG: Leukemia/heme
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: NOVARTIS

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

    Eligibility Criteria - NCT04266301 *This information has been extracted from " www.clinicaltrials.gov"

  • AG120-C-001 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Alessia Zoso
    RCphone +1 (305) 2432373

    IRB: 20140124

    SDG: Leukemia/heme
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Agios

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation.

    Eligibility Criteria - NCT02074839 *This information has been extracted from " www.clinicaltrials.gov"

  • H3B-8800-G000-101 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20170778

    SDG: Leukemia/heme
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: H3BIO

    Enrolling Sites:

    Sylvester

    Title:

    H3B-8800-G000-101: An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

    Eligibility Criteria - NCT02841540 *This information has been extracted from " www.clinicaltrials.gov"

  • S17-00978 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20180143

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other

    Sponsor: NYULMC

    Enrolling Sites:

    Sylvester

    Title:

    S17-00978:A Phase Ib/IIa Study Evaluating the Safety and Tolerability ofVitamin C in Patients with Intermediate or high Risk Myelodysplastic Syndrome with TET2 Mutations

    Eligibility Criteria - NCT03433781 *This information has been extracted from " www.clinicaltrials.gov"

  • 5001 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20180739

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other,Myeloid and Monocytic Leukemia

    Sponsor: Aptevo Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1b Open-Label, Dose-Escalation And Dose-Expansion Study of APVO436 In Patients With Advanced High Risk Leukemias, Including Relapsed or Refractory AML, or High-Grade MDS

    Eligibility Criteria - NCT03647800 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190675 - Watts Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20190675

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other,Myeloid and Monocytic Leukemia

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester

    Title:

    An Open-Label Phase 1b Study of NEROFE, a Novel Hormone-Peptide in Adult Patients with Advanced Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

    Eligibility Criteria - NCT04365179 *This information has been extracted from " www.clinicaltrials.gov"

  • INCB057643 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20200314

    SDG: Leukemia/heme
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Incyte Corporation

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced MyeloidNeoplasms

    Eligibility Criteria - NCT04279847 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211034 - Watts Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20211034

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other

    Sponsor: BioSight Ltd

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy With Relapsed or Refractory AML or Higher-Risk Myelodysplastic Syndromes

    Eligibility Criteria - NCT04749355 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211090 - Watts Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20211090

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, not otherwise specified

    Sponsor: Sumitomo Dainippon Pharma Oncology

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients With and Without Mixed Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation

    Eligibility Criteria - NCT04988555 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211172 - Watts Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Chenice Fenty
    RCphone +1 (305) 2433450

    IRB: 20211172

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, not otherwise specified

    Sponsor: Imago

    Enrolling Sites:

    Sylvester

    Title:

    A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients with Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study

    Eligibility Criteria - NCT04254978 *This information has been extracted from " www.clinicaltrials.gov"